Tuesday 16 June 2009
Co-organiser UK Trade & Investment
Co-organiser: Asia Pacific Technology Network
This is the third in the “Japan/UK Life Science Seminar Series” organised by the UK Trade & Investment and the Asia Pacific Technology Network. These quarterly seminars will provide an opportunity for UK and Japanese companies in the pharmaceutical, biotechnology and healthcare sectors to network, develop commercial ties and understand one another’s markets better.
Location: Department for Business Conference Centre, 1 Victoria Street, London, SW1H 0ET
Nearest tube stations: St James Park or Westminster
Timing: Registration at 17.30: Session at 18.00: Networking and refreshments 19.45: finish 21.00
Pricing: £20 + VAT
To Register: Please send Name and Institutional Affiliation to firstname.lastname@example.org
Dr. Koseki is a founder and director of transBLtd. She was also a board of director of Stelic Institute & Co., Tokyo-based privately owned Japanese biotech company until Nov 2008. Former to founding transB Ltd., she served as a vice president of Sosei Co. Ltd (4565, MOTHERS index) based in its UK operation for 8 years. She played a major role in establishing its unique business model, drug reprofiling platform (DRP®) . Prior to joining Sosei, she was working based in the UK as a consultant for various Japanese health care companies. Formerly, she held various positions as a researcher including a section chief in National Cardiovascular Research Institute (Japan), a visiting scientist in Colombia and Florida universities (USA), and an associate professor in Tokyo University (Japan). She holds Ph.D in pharmacology from Tokyo University.
received a BSc in Pharmacy from Heriot-Watt University in 1980 and a PhD from the University of Strathclyde in 1985. He has worked in the pharmaceutical industry for 25 years for a various Pharmaceutical Companies in UK, USA and Switzerland. He joined Takeda in 2003 and currently serves as head of Clinical Pharmacology in Takeda Global Research & Development (Europe) based in central London.
Who should attend?